Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study

C. A. Nava-Valdivia, J. M. Ponce-Guarneros, A. M. Saldaña-Cruz, E. G. Corona-Sanchez, M. Ramirez-Villafaña, E. E. Perez-Guerrero, J. D. Murillo-Saich, B. Contreras-Haro, M. L. Vazquez-Villegas, F. Gonzalez-Ponce, D. Bonilla-Lara, H. Jacobo-Cuevas, J. D. Centeno-Valadez, G. Echeverria-Gonzalez, S. Cerpa-Cruz, M. F. Alcaraz-Lopez, E. G. Cardona-Muñoz, M. Salazar-Paramo, L. Gonzalez-Lopez, L. Gonzalez-Lopez, L. Gonzalez-Lopez, L. Gonzalez-Lopez, L. Gonzalez-Lopez, L. Gonzalez-Lopez, and J. I. Gamez-Nava

1Departamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
2Unidad Médica Familiar 97, Instituto Mexicano del Seguro Social (IMSS), 46470 Magdalena, JAL, Mexico
3Instituto de Terapéutica Experimental y Clínica (INTEC), Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
4Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
5Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
6Instituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
7Department of Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA
8Departamento de Ciencias Biomédicas, Centro Universitario de Tonalá, Universidad de Guadalajara, 45425 Tonalá, JAL, Mexico
9Programa de Doctorado en Ciencias de la Salud Pública, Departamento de Salud Pública, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
10Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
11Departamento de Reumatología, Hospital de Especialidades, Instituto Mexicano del Seguro Social, 44329 Guadalajara, JAL, Mexico
12División de Reumatología, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, 44280, Guadalajara, JAL, Mexico
13Departamento de Medicina Interna-Reumatología, Hospital General Regional 46, IMSS, 44910 Guadalajara, JAL, Mexico
14Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, IMSS, 44716, Guadalajara, JAL, Mexico
15Unidad de Investigación Biomédica 02, División de Investigación, Hospital de Especialidades, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), 44340 Guadalajara, JAL, Mexico

Correspondence should be addressed to L. Gonzalez-Lopez; lauraacademicoudg@gmail.com and J. I. Gamez-Nava; ivangamezacademicoudg@gmail.com

Received 23 February 2021; Accepted 14 August 2021; Published 30 August 2021

Academic Editor: Nadeem Sheikh

Copyright © 2021 C. A. Nava-Valdivia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by an imbalance of cellular, pro-inflammatory mediators, and autoantibodies that lead to synovial joint inflammation and the destruction of cartilage and bone in severe cases [1, 2]. The overall progressive bone loss has been considered a risk factor for osteoporosis in patients with RA due to inherent factors related to the disease [3]. Osteoporosis is highly prevalent in RA patients (38.6%) [4]. In Mexican women with RA, the prevalence of osteoporosis is around 24% [5]. The current gold standard for diagnosis of osteoporosis measures of bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) [6]; therefore, the determination of BMD is mandatory in patients with RA.

However, in addition to measuring BMD, other risk factors of osteoporosis have been incorporated into risk assessment tools to predict the development of osteoporotic fractures. One of the main tools developed for this purpose is the fracture risk assessment tool (FRAX), which is an algorithm developed to estimate the 10-year risk of major osteoporotic fractures or the 10-year risk of a hip fracture. To calculate FRAX scores, total hip BMD values can be alternatively introduced in the formula [7]. Studies report a significant increase in the risk of fracture in patients with RA compared to the healthy population [8]. Furthermore, several studies have evaluated the relevance of the FRAX score in RA patients. Phuan-Udom et al. found an association between the FRAX score with disease duration, disease activity, and functional disability in RA patients [9]. Cheng et al. observed that the 10-year probability of fracture increase in anti-CCP positive patients with RA [10].

Whereas several bone turnover markers (BTMs) have been used in nonrheumatic population to assess the risk of osteoporosis independently of BMD values by DXA [6, 11], one of the advantages of BTMs is that they measure the rate of bone remodeling changes [12]. Furthermore, serum biomarkers of bone resorption such as soluble ligand of receptor activator of nuclear factor-κB (sRANKL), osteoprotegerin (OPG), and other molecules related with secondary osteoporosis in rheumatoid arthritis (RA). Therefore, this study is aimed at assessing the correlation between the FRAX and serum levels of sRANKL, OPG, sRANKL/OPG ratio, Dickkopf-1 (DKK-1), and sclerostin (SOST) in RA.

Methods. Cross-sectional study included 156 postmenopausal women with RA. Bone mineral density (BMD) was measured at lumbar spine (L1-L4) and total hip using dual-energy X-ray absorptiometry (DXA). RA patients were divided into (A) RA + osteoporosis and (B) RA without osteoporosis. FRAX scores were calculated including the total hip BMD. Serum sRANKL, OPG, DKK-1, and SOST levels were measured by ELISA. Pearson tests were used for assessing the correlation between serum levels of these molecules and FRAX scores in RA. The RA + osteoporosis group had elevated sRANKL levels (p = 0.005), higher sRANKL/OPG ratio (p = 0.017), decreased DKK-1 (p = 0.028), and lower SOST levels (p < 0.001). Low total hip BMD correlated with high sRANKL (p = 0.001) and sRANKL/OPG ratio (p = 0.005). Total hip and lumbar spine BMD correlated with DKK-1 (p = 0.009 and p = 0.05, respectively) and SOST levels (p < 0.001 and p < 0.001, respectively). Higher sRANKL levels and sRANKL/OPG ratio correlated with estimated 10-year risk of a major osteoporotic fractures (p = 0.003 and p = 0.003, respectively) and hip fracture (p = 0.002 and p = 0.006, respectively). High serum SOST levels were associated with a low estimated 10-year risk of a major osteoporotic fracture (p = 0.003) and hip fracture (p = 0.009). Conclusion. High sRANKL levels and sRANKL/OPG ratio can be useful to detect a subgroup of RA patients who has an increased 10-year risk of major and hip osteoporotic fractures.

2. Materials and Methods

2.1. Study Design. Cross-sectional.

2.2. Clinical Setting. RA patients referred to undergo bone densitometry at a tertiary care center were recruited from a public hospital of the Mexican Institute of Social Security (Hospital de Especialidades, Centro Medico Nacional de Occidente, Instituto Mexicano del Seguro Social) in Guadalajara, Mexico.

2.3. Inclusion and Exclusion Criteria. We included 156 consecutive Mexican postmenopausal women with RA who met the following inclusion criteria: (1) female gender, (2) postmenopausal diagnosis, and (3) established RA according to the American College of Rheumatology (ACR, 1987) criteria.
Rheumatoid factor (RF) concentrations were quantified using nephelometry. Second-generation anticyclic-citrullinated peptide (anti-CCP2) was quantified by enzyme-linked immunosorbent assay (ELISA) (Euroimmun AG, Luebeck, Germany. Sensitivity 0.2 RU/mL). Anti-CCP2 positivity was considered by ELISA with a commercial kit (Orgentec Diagnostika GmbH, Mainz, Germany; assay sensitivity of 1.0 UI/mL, and a value of ≥20 UI/mL was considered positive. Serum levels of tumor necrosis factor-alpha (TNF-α) were quantified by ELISA using a commercial kit (R&D Systems Inc., Minneapolis, MN, USA; assay sensitivity of 5.5 pg/mL).

2.8. Measurement of Bone Turnover Markers. Serum levels of sRANKL, OPG, DKK-1, SOST, and other markers were quantified by ELISA using commercial kits: sRANKL (Biovendor Laboratorni Medina A. S., Brno, Czech Republic; assay sensitivity of 0.4 pmol/L), OPG (RayBiotech Inc., Norcross, GA, USA; assay sensitivity of 1.0 pg/mL), DKK-1 (R&D Systems Inc., Minneapolis, MN, USA; assay sensitivity of 0.94 pg/mL), SOST (R&D Systems Inc., Minneapolis, MN, USA; assay sensitivity of 0.37 pg/mL), OC (osteocalcin) (Quidel Corporation, San Diego, CA, USA; assay sensitivity of 0.47 ng/mL), and CTSK (cathepsin k) (MyBioSource, Inc., San Diego, CA, USA; assay sensitivity of 0.1 ng/mL).

All procedures were performed according to manufacturer’s recommendations. sRANKL/OPG ratio was also calculated. All measurements were performed by the same researchers who were blind to the clinical characteristics of patients to avoid measurement biases.

2.9. Statistical Analysis. Qualitative variables were expressed as frequencies (%) and quantitative variables as means ± standard deviations (SD). The comparisons of proportions between study groups were analysed using Chi-square tests (or Fisher’s exact tests, if required). The comparison of means between the study groups RA + osteoporosis and RA without osteoporosis groups was performed using the Student’s unpaired t-test. Correlations between sRANKL, OPG, DKK-1, SOST, and other BTMs with clinical and laboratory variables were calculated using Pearson correlation tests. Statistical significance was set at a p value ≤ 0.05. All statistical analyses were performed using R version 4.0.0 [20] and GraphPad Prism software version 7.00 (San Diego, California, USA).

3. Results

This study included 156 postmenopausal women with RA, of which, 49.4% had osteoporosis. The prevalence of osteoporosis in total hip was 40.4% (n = 63), and the frequency of osteoporosis at the lumbar spine was 35.3% (n = 55) (data not shown).

Of 125 RA patients (80%), who received pharmacological treatment with conventional synthetic-disease-modifying antirheumatic drugs (cs-DMARDs), of which, 36.5% (n = 57) were treated with a monotherapy scheme, and 43.6% (n = 68) received a combination of two or more cs-DMARDs. Methotrexate was the cs-DMARD most frequently prescribed (46.2%, n = 72), followed by leflunomide (30.1%, n = 47), sulfasalazine (28.8%, n = 45), chloroquine (14.1%, n = 22), and azathioprine (13.5%, n = 21). There were no statistical differences in the type of cs-DMARDs used between groups (data not shown).
Table 1: Comparison of selected patient characteristics between the groups with rheumatoid arthritis with osteoporosis vs. without osteoporosis.

| Clinical features                      | RA+ osteoporosis n=77 | RA without osteoporosis n=79 | p     |
|---------------------------------------|-----------------------|-----------------------------|-------|
| Females, n (%)                        | 77 (100)              | 79 (100)                    | —     |
| Age (yr), mean ± SD                   | 63 ± 9                | 56 ± 10                     | <0.001|
| Body mass index (kg/m²), mean ± SD    | 26.6 ± 4.5            | 29.2 ± 4.3                  | <0.001|
| Disease characteristics               |                       |                             |       |
| Disease duration (yr), mean ± SD      | 14 ± 10               | 11 ± 9                      | 0.058 |
| Menopausal duration (yr), mean ± SD   | 17 ± 10               | 10 ± 9                      | <0.001|
| DAS28 score, mean ± SD                | 3.7 ± 1.4             | 3.3 ± 1.4                   | 0.086 |
| HAQ-Di score, mean ± SD               | 0.52 ± 0.51           | 0.41 ± 0.56                 | 0.173 |
| ESR (mm/hr), mean ± SD                | 28 ± 11               | 23 ± 10                     | 0.006 |
| Rheumatoid factor (UI/mL), mean ± SD  | 157.6 ± 489.5         | 81.7 ± 135.8                | 0.186 |
| Tumor necrosis factor-α (pg/mL), mean ± SD | 22.9 ± 38.8          | 26.3 ± 84.2                 | 0.711 |
| ACPAs (+), n (%)                      | 59 (76.6)             | 53 (67.1)                   | 0.215 |
| Anti-CCP2 (+), n (%)                  | 45 (58.4)             | 47 (59.5)                   | 1.000 |
| Anti-MCV (+), n (%)                   | 51 (66.2)             | 40 (50.6)                   | 0.053 |
| Anti-MCV (U/mL), mean ± SD            | 231.8 ± 313.3         | 185.1 ± 317.2               | 0.356 |
| Treatment characteristics            |                       |                             |       |
| cs-DMARD use, n (%)                   | 62 (80.5)             | 63 (79.7)                   | 1.000 |
| Monotherapy (1 cs-DMARD), n (%)       | 27 (43.5)             | 30 (47.6)                   | 0.721 |
| Politherapy (2 cs-DMARD or more), n (%)| 33 (52.4)             | 35 (56.5)                   | 0.721 |
| Glucocorticoid use, n (%)             | 64 (83.1)             | 62 (78.5)                   | 0.544 |
| Glucocorticoid dose (mg/day), mean ± SD| 5.9 ± 6.9             | 4.8 ± 4.8                   | 0.241 |
| Biomarker serum levels                |                       |                             |       |
| sRANKL (pmol/L), mean ± SD            | 1063.7 ± 1257.1       | 602.3 ± 634.1               | 0.005 |
| OPG (pg/mL), mean ± SD                | 113.8 ± 85.4          | 119.2 ± 89.4                | 0.670 |
| sRANKL/OPG ratio                      | 14.1 ± 21.6           | 7.6 ± 9.1                   | 0.017 |
| DKK-1 (pg/mL), mean ± SD              | 204.1 ± 191.8         | 279.4 ± 230.2               | 0.028 |
| SOST (pg/mL), mean ± SD               | 114.1 ± 56.2          | 163.5 ± 102.9               | <0.001|
| OC (ng/mL), mean ± SD                 | 4.8 ± 4.6             | 5.9 ± 5.9                   | 0.190 |
| CTSK (pg/mL), mean ± SD               | 3.1 ± 1.6             | 2.9 ± 1.3                   | 0.494 |

DAS28: Disease Activity Score for 28 joints; HAQ-DI: Health Assessment Questionnaire Disability Index; BMD: bone mineral density; ESR: erythrocyte sedimentation rate; ACPAs: antibodies against cyclic-citrullinated peptides/proteins included anti-CCP2 or anti-MCV; cs-DMARD: conventional synthetic-disease-modifying antirheumatic drugs; sRANKL: Soluble Receptor Activator for Nuclear Factor kappa B Ligand; OPG: osteoprotegerin; DKK-1: Dickkopf-1; SOST: sclerostin; OC: osteocalcin; CTSK: cathepsin k. Qualitative variables were expressed in frequencies (%) and quantitative variables in means ± standard deviations (SD). Statistical tests: Chi-square test (or Fisher exact test if applicable) for comparisons between proportions. Independent sample Student t-tests were conducted for comparisons between means, and p values were obtained comparing RA patients with osteoporosis vs. RA patients without osteoporosis. The group of patients without osteoporosis included patients with osteopenia or with normal BMD (T score higher than −2.5 SD).

Table 1 compares the clinical characteristics between the RA + osteoporosis group (n = 77) versus the RA without osteoporosis group (n = 79). The RA + osteoporosis group had a higher age range (63 vs. 56 years, p < 0.001), lower BMI (26.6 vs. 29.2 kg/m², p < 0.001), longer period from the onset of menopause (17 vs. 10 years, p < 0.001), and higher ESR levels (28 vs. 23 mm/h, p = 0.006). The RA + osteoporosis group had a similar frequency of anti-CCP positivity (58.4% vs. 59.5%, p = 1.0). A nonsignificant trend of increased RA disease duration was observed in patients with RA + osteoporosis (14 vs. 11 years, p = 0.058) and a higher frequency of anti-MCV antibodies (66.2% vs. 50.6%, p = 0.053). Patients with RA + osteoporosis had higher sRANKL levels (1063.7 vs. 602.3 pmol/L, p = 0.005), higher sRANKL/OPG ratio (14.1 vs. 7.6, p = 0.017), lower serum concentrations of DKK-1 (204.1 vs. 279.4 pg/mL, p = 0.028), and decreased serum SOST levels compared with RA patients without osteoporosis (114.1 vs. 163.5 pg/mL, p < 0.001). There were no significant statistical differences between both study groups in the other biomarkers (Figure 1).
Figure 1: Comparison between the serum levels of molecules associated with bone remodeling between the RA + osteoporosis and RA without osteoporosis groups. p values were obtained using Student’s t-test. Figure 1 shows the comparisons of the following serum markers: (a) sRANKL levels; (b) OPG levels; (c) sRANKL/OPG ratio; (d) DKK-1 levels; (e) SOST levels; (f) osteocalcin levels; (g) cathepsin k levels.
Table 2: Correlations of bone mineral density in two regions in RA patients with clinical characteristics, serological features, and bone biomarker serum levels.

| Clinical characteristics and serological features | Total hip BMD (g/cm²) | Lumbar spine BMD (g/cm²) |
|--------------------------------------------------|-----------------------|--------------------------|
| Age (yr)                                          | \( r = -0.462 \)       | \( r = -0.380 \)         |
| Body mass index (kg/cm²)                         | \( r = 0.275 \)        | \( r = 0.179 \)          |
| Disease duration (yr)                            | \( r = -0.234 \)       | \( r = -0.015 \)         |
| Menopausal duration (yr)                         | \( r = -0.385 \)       | \( r = -0.348 \)         |
| DAS28 score                                      | \( r = -0.121 \)       | \( r = 0.003 \)          |
| HAQ-DI score                                     | \( r = -0.058 \)       | \( r = 0.026 \)          |
| ESR (mm/hr)                                      | \( r = -0.236 \)       | \( r = -0.103 \)         |
| Rheumatoid factor (UI/mL)                        | \( r = -0.101 \)       | \( r = -0.052 \)         |
| Tumor necrosis factor-α (pg/mL)                  | \( r = 0.025 \)        | \( r = 0.076 \)          |
| Anti-CCP2 (RU/mL)                                | \( r = -0.053 \)       | \( r = -0.064 \)         |
| Anti-MCV (U/mL)                                  | \( r = -0.154 \)       | \( r = -0.012 \)         |
| Glucocorticoid dose (mg)                         | \( r = -0.031 \)       | \( r = -0.108 \)         |
| Biomarker serum levels                           | \( r = 0.267 \)        | \( r = 0.044 \)          |
| sRANKL (pmol/L)                                  | \( r = 0.007 \)        | \( r = 0.077 \)          |
| OPG (pg/mL)                                      | \( r = -0.222 \)       | \( r = -0.043 \)         |
| DKK-1 (pg/mL)                                    | \( r = 0.209 \)        | \( r = 0.157 \)          |
| SOST (pg/mL)                                     | \( r = 0.317 \)        | \( r = 0.370 \)          |
| OC (ng/mL)                                       | \( r = 0.085 \)        | \( r = 0.085 \)          |
| CTSK (pg/mL)                                     | \( r = -0.006 \)       | \( r = -0.125 \)         |

BMD: bone mineral density; DAS28: Disease Activity Score for 28 joints; HAQ-DI: Health Assessment Questionnaire Disability Index; ESR: erythrocyte sedimentation rate; anti-CCP2: 2nd-generation antibodies against citrullinated proteins; anti-MCV: antimutated citrullinated vimentin antibodies; sRANKL: Soluble Receptor Activator for Nuclear Factor kappa B Ligand; OPG: osteoprotegerin; DKK-1: Dickkopf-1; SOST: sclerostin; OC: osteocalcin; CTSK: cathepsin k. Correlations between biomarker serum levels and quantitative variables were performed using Pearson test.

Table 2 shows the correlations between the total hip and lumbar spine BMD (in g/cm²) with bone marker levels and other features. Total hip BMD negatively correlated with age \( (p < 0.001) \), RA disease duration \( (p = 0.003) \), the duration of menopause \( (p < 0.001) \), ESR \( (p = 0.003) \), sRANKL levels \( (p = 0.001) \), and the sRANKL/OPG ratio \( (p = 0.005) \), while increased total hip BMD correlated with BMI \( (p = 0.001) \), higher DKK-1 \( (p = 0.009) \), and SOST serum levels \( (p < 0.001) \). Lumbar spine BMD negatively correlated with age \( (p < 0.001) \) and duration of menopause \( (p < 0.001) \). The increased lumbar spine BMD correlated with an elevated BMI \( (p = 0.025) \), high DKK-1 \( (p = 0.050) \), and SOST serum levels \( (p < 0.001) \).

The sRANKL serum levels correlated positively with long RA disease duration \( (r = 0.172, p = 0.031) \), ESR \( (r = 0.257, p = 0.001) \), and anti-MCV levels \( (r = 0.404, p < 0.001) \). The OPG had a positive correlation with CTSK serum levels \( (r = 0.166, p = 0.038) \). The sRANKL/OPG ratio correlated positively with ESR \( (r = 0.209, p = 0.009) \) and anti-CCP titers \( (r = -0.359, p < 0.001) \). DKK-1 levels correlated with SOST levels \( (r = 0.181, p = 0.024) \) and ESR \( (r = 0.200, p = 0.012) \), whereas DKK-1 had a negative correlation with age \( (r = -0.255, p = 0.001) \). SOST levels were negatively correlated with anti-CCP concentrations \( (r = -0.213, p = 0.008) \), age \( (r = -0.177, p = 0.027) \), and the duration of menopause \( (r = -0.165, p = 0.040) \). Serum CTSK levels correlated with OPG levels \( (r = 0.166, p = 0.038) \) and the glucocorticoid dose administered per day \( (r = 0.225, p = 0.005) \). OC levels did not have significant correlation with other variables (data not shown in tables).

The prevalence of RA patients with high risk of major osteoporotic fracture (FRAX score > 20%) was 12.8% \( (n = 20) \), whereas 27.6% \( (n = 43) \) had a moderate risk of major osteoporotic fracture (FRAX score 10-20%), and 59.6% \( (n = 93) \) of the RA patients had a low risk of a major osteoporotic fracture (FRAX score < 10%). Also, the prevalence of RA patients with high risk of hip fracture (FRAX score > 10%) was 10.9% \( (n = 17) \); 23.7% \( (n = 37) \) had a moderate risk of hip fracture (FRAX score 3-10%), and 65.4% \( (n = 102) \) had a low risk of a hip fracture (FRAX score < 3%) (Data not shown).

Table 3 shows the correlations between the clinical variables, laboratory features, serum bone biomarker concentrations, and the 10-year risk of hip and major osteoporotic fractures according to the FRAX score. Serum sRANKL levels correlated with a higher 10-year risk of major osteoporotic fractures \( (p = 0.003) \) and a higher 10-year risk of hip fractures \( (p = 0.002) \). Likewise, the sRANKL/OPG ratio...
correlated with a higher 10-year risk of major osteoporotic fractures \((p = 0.009)\) and higher risk to hip fractures \((p = 0.006)\). In addition, increased serum SOST levels correlated negatively with the 10-year risk assessment of major osteoporotic fractures \((p = 0.003)\) and with the 10-year risk of hip fractures \((p = 0.009)\) (Figure 2).

### 4. Discussion

We identified a significant increase of sRANKL levels and the sRANKL/OPG ratio in RA patients with osteoporosis. Furthermore, sRANKL levels and sRANKL/OPG ratio were both correlated with a low total hip BMD and higher FRAX scores, indicating that these patients had an increase 10-year risk of major and hip osteoporotic fractures. Instead, higher DKK-1 and SOST levels were identified in RA patients without osteoporosis patients, correlating with high total hip and lumbar spine BMD, as well as with a decreased of major and hip osteoporotic fracture assessed by FRAX.

In the present study, the prevalence of osteoporosis in RA was 49.4%, in total hip 40.4%, and in lumbar spine 35.3%. This prevalence was similar in different studies according to a meta-analysis by Wang et al. where the pooled prevalence of osteoporosis in the lumbar spine was 32.9% \((range\ from\ 27.7\%\ to\ 38.1\%)\) and 21.7% in the femur \((range\ from\ 10.6\%\ to\ 32.8\%\) \[4\]. The prevalence of central osteoporosis in our study was similar to a study by Lee et al. in Korean RA patients whose osteoporosis prevalence was 46.8% \[21\].

We observed a 12.8% of high risk of major osteoporotic fractures and 10.9% of high risk of hip fracture in RA patients. These findings were similar to those reported by Phuan-Udom et al., in RA patients \[9\]. This result confirms the high prevalence of high risk of osteoporotic fractures in RA.

RANKL is a type II membrane protein, expressed by osteoblasts, stromal cells, and T lymphocytes \[22\]. This molecule is secreted to the extracellular medium and binds to RANK, which is the natural receptor present in immature osteoclasts. The link RANKL to RANK unchains the maturation and activation of osteoclasts required for bone resorption \[23\]. An overexpression of RANK and RANKL developed by the overactivation of T cells leads to the increased production of RANKL released to the circulating blood that has been observed in RA patients. Additionally, RANKL is released into the synovium joint of these patients and binds to the RANK receptor in osteoclasts, which accelerates the bone resorption process. Therefore, an increase in the link between RANKL with RANK contributes to a low BMD in RA patients \[23\]. On the other hand, OPG is a soluble protein secreted by osteoblasts that exerts an opposite effect on bone turnover, acting as a decoy receptor for RANKL and thereby inhibiting osteoclast activation and bone resorption.

### Table 3: Correlations of estimated in 10-year of major osteoporosis fracture risk, hip fracture risk (FRAX score), and biomarker serum levels.

| Clinical characteristics and serological features | Estimated 10-year of major osteoporosis fracture risk (FRAX score) | Estimated 10-year of hip fracture risk (FRAX score) |
|-------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------|
| RA disease duration (yr)                        | \(0.230\) \(p = 0.004\)                                      | \(0.225\) \(p = 0.005\)                          |
| Menopausal duration (yr)                        | \(0.431\) \(< 0.001\)                                      | \(0.306\) \(< 0.001\)                           |
| DAS28 score                                     | \(-0.003\) \(0.975\)                                       | \(0.015\) \(0.857\)                            |
| HAQ-Di score                                    | \(-0.023\) \(0.777\)                                       | \(-0.042\) \(0.607\)                          |
| ESR (mm/hr)                                     | \(0.261\) \(0.001\)                                       | \(0.243\) \(0.002\)                           |
| Rheumatoid factor (UI/mL)                       | \(0.061\) \(0.453\)                                       | \(0.071\) \(0.377\)                           |
| Tumor necrosis factor-\(\alpha\) (pg/mL)       | \(-0.075\) \(0.350\)                                       | \(-0.052\) \(0.521\)                          |
| Anti-CCP2 (RU/mL)                               | \(0.038\) \(0.641\)                                       | \(-0.012\) \(0.882\)                          |
| Anti-MCV (U/mL)                                 | \(0.082\) \(0.310\)                                       | \(0.104\) \(0.198\)                           |
| Treatment characteristics                      |                                                              |                                                   |
| Glucocorticoid dose (mg)                        | \(-0.013\) \(0.876\)                                       | \(-0.016\) \(0.838\)                          |
| Biomarker serum levels                          |                                                              |                                                   |
| Serum sRANKL levels (pmol/L)                    | \(0.237\) \(0.003\)                                       | \(0.244\) \(0.002\)                           |
| Serum OPG levels (pg/mL)                        | \(-0.012\) \(0.881\)                                       | \(-0.006\) \(0.942\)                          |
| sRANKL/OPG ratio                               | \(0.208\) \(0.009\)                                       | \(0.217\) \(0.006\)                           |
| Serum DKK-1 levels (pg/mL)                      | \(-0.131\) \(0.144\)                                       | \(-0.110\) \(0.173\)                          |
| Serum SOST levels (pg/mL)                       | \(-0.240\) \(0.003\)                                       | \(-0.209\) \(0.009\)                          |
| Serum OC levels (ng/mL)                         | \(-0.059\) \(0.468\)                                       | \(-0.029\) \(0.720\)                          |
| Serum CTSL levels (pg/mL)                       | \(-0.015\) \(0.848\)                                       | \(-0.053\) \(0.515\)                          |

**FRAX:** fracture risk assessment tool; **DAS28:** Disease Activity Score for 28 joints; **HAQ-DI:** Health Assessment Questionnaire Disability Index; **ESR:** erythrocyte sedimentation rate; **ACPAs:** antibodies against cyclic-citrullinated peptides/proteins included anti-CCP2 or anti-MCV; **sRANKL:** Soluble Receptor Activator for Nuclear Factor kappa B Ligand; **OPG:** osteoprotegerin; **DKK-1:** Dickkopf-1; **SOST:** sclerostin; **OC:** osteocalcin; **CTS:** cathepsin.
effect, acting as a protective molecule for bone resorption [24]. OPG is a decoy receptor of RANKL that inhibits the maturation and activation of osteoclasts through competition between the binding of RANKL and RANK [22]. In osteoporosis associated with RA, we did not observe an increase in OPG levels to protect BMD. It has been observed that some risk factors of osteoporosis increase the production of proinflammatory cytokines, particularly IL-1β and IL-6, and can decrease OPG serum levels [25]. All these factors are present in RA patients, leading to the high prevalence of osteoporosis found in our study.

When we investigated the association between sRANKL levels and osteoporosis in RA patients, we found in the correlation analysis, a correlation between high sRANKL levels with a low total hip BMD. This finding was similar to those obtained in previous studies on a postmenopausal nonrheumatic population and RA patients [14, 26]. Nabipour et al. identified that a low femoral neck BMD was associated with high sRANKL levels [26]. On the other side, Oelzner et al. observed that a low femoral neck BMD was associated with high sRANKL levels in RA patients [14]. Similarly, Xu et al. also identified an association between high sRANKL levels and low femoral neck BMD in RA patients compared to controls [13].

In contrast, Liu et al. did not observe association between sRANKL with osteoporosis among postmenopausal
nonrheumatic patients [27]. In this study, we did not observe an association between low serum OPG levels and osteoporosis in RA patients. These findings support the results by Oelsner et al., where no association was found between OPG levels and the femoral neck or lumbar spine BMD [14]. On the other hand, Xu et al. observed an association between high OPG levels and an increased femoral neck and lumbar spine BMD [13].

We observed that RA patients with osteoporosis had a significant increase of the sRANKL/OPG ratio. These findings are in line with those of Nabipour et al. who also observed that a low femoral neck BMD was associated with an increase of the sRANKL/OPG ratio [26].

We found a correlation between FRAX scores for the 10-year probability of a major osteoporotic fractures and 10-year probability of a hip fracture with higher serum levels of sRANKL and sRANKL/OPG ratio. These findings agree with our hypothesis that sRANKL and sRANKL/OPG ratio are linked to an increased risk of major osteoporotic and hip fracture. To the best of our knowledge, there are no previous studies published in the literature evaluating the correlation between FRAX score and sRANKL or OPG levels in RA. Mykhailovska et al. reported in a group of patients with coronary artery disease an association between the serum OPG levels with an increase in the FRAX score for the risk of radial osteoporotic fracture [28]. We did not observe any correlation between serum OPG levels with the FRAX scores.

DKK-1 is a molecule expressed by osteoblasts that inhibits the Wingless tail (Wnt)/β-catenin pathway, a relevant system that participates in bone remodeling and plays a key role in the cell signaling, proliferation, and differentiation of preosteoblastic cells, and inhibits their apoptosis [29–31]. DKK-1 is recognized as an inhibitor of the Wnt/β-catenin pathway. DKK-1 is also secreted by synovial fibroblasts, chondrocytes, and mature osteocytes [32–34]. Under normal conditions, an increase in DKK-1 is related to a reduction in bone formation [35].

On the other hand, SOST is a glycoprotein expressed and secreted by mature osteocytes and joint chondrocytes. SOST binds to the LRPS/6 receptor and inhibits signaling of the WNT-β catenin pathway, causing a reduction in bone formation [36, 37]. Among the factors involved in the serum level increase of these molecules, the expression of SOST in fibroblast-like synoviocytes in RA and the poor relationship between gene expression and SOST serum concentrations have been reported [38, 39]. In animal models of adjuvant-induced arthritis, SOST and DKK-1 can be overexpressed initially, and later, a decrease in bone mass formation is observed; in spite of this, SOST and DKK-1 can return to normal values [40].

We investigated whether DKK-1 and SOST serum levels are biomarkers of osteoporosis in RA patients. Contrary to our primary hypothesis, we found that high levels of DKK-1 were associated with high total hip and lumbar spine BMD, and DKK-1 values were higher in patients without osteoporosis. Similar to our findings, Ueland et al. observed that cortical bone matrix levels of DKK1 and SOST were correlated with bone mass in postmenopausal women without rheumatic disease [41]. These findings reflect the complexity of the dynamic behaviour of this serum marker.

In the correlation analysis, we found that DKK-1 and SOST levels correlated with an increase in total hip BMD. RA patients with osteoporosis had higher DKK-1 and SOST levels than RA patients without osteoporosis. These findings are in contrast to those observed by Rossini et al. who found increased in serum DKK-1 levels correlated with a low total hip BMD [15]. In postmenopausal patients without rheumatic disease, discrepant results of the relationship between DKK-1 and BMD were also observed. Ardawi et al. reported a negative correlation between serum DKK-1 levels and BMD of the lumbar spine, femoral neck, and total hip in a nonrheumatic population [42]. Similarly, Coulson et al. described an association between DKK-1 levels and low BMD in people without inflammatory rheumatic disorders [43]. The results of our study differ from those described by Rossini et al. because we identified a positive correlation between DKK-1 concentrations and an increase in total hip BMD. Different reasons could explain these differences. Particularly, we avoided the inclusion of potential confounders, including drugs that could influence BMD. In contrast, in Rossini’s study, the use of biologic agents and bisphosphonates was 30% and 44%, respectively [15].

We identified that RA patients with osteoporosis had increased SOST levels. Nevertheless, there are a few studies that have examined the relationship between SOST levels and BMD in RA patients. Therefore, we compared our findings mainly with those observed in nonrheumatic population. Garnero et al., in postmenopausal osteoporosis without rheumatic inflammatory disorders, identified that high SOST levels correlated with an increase in total hip and lumbar spine BMD [37]. However, other authors have observed different results. Ardawi et al. reported a negative correlation between serum SOST levels and BMD for the lumbar spine, femoral neck, and total hip in nonrheumatic population [42]. Some authors have also found an association between increased SOST levels and low BMD in postmenopausal patients without rheumatic disorders [37, 44]. Similar to our findings, Paccou et al. observed a positive correlation between serum SOST levels and the lumbar spine BMD [16]. In addition, Paccou et al. and Arasu et al. hypothesized that the correlation observed between SOST levels and an increase in BMD could be associated with an increase in the number of osteocytes producing circulating SOST [16, 44]. Meanwhile, Reppe et al. reported a correlation between SOST levels, and an increase in BMD could be associated with an increased methylation in the SOST gene promoter region by epigenetic mechanisms in osteoporosis of nonosteoporotic postmenopausal women [45]. These findings require further investigation in terms of the kinetics of SOST and DKK-1 in human patients with RA.

We identified that increase on the serum SOST levels correlated with high FRAX scores of the 10-year risk of major and hip osteoporotic fractures. We did not find other published studies that assessed the correlation between SOST levels and FRAX scores; therefore, our findings should be corroborated by future studies. It has been proposed by some authors that the paradoxical high serum levels of SOST
in some patients with osteoporosis may be associated with a feedback loop in response to the loss of bone mass [16, 44]. In consequence, we can hypothesize that this increase in serum SOST levels can be an adaptive response to the osteoporosis observed in our patients, and future studies should be performed to determine whether these levels constituted a risk factor for osteoporotic fractures. Similar to our findings, Arasu et al. identified in women without rheumatic diseases that high serum levels of SOST and a higher FRAX score, thus pointing out to a higher risk of hip fractures [44].

One of the main strengths of this study was the inclusion of a broader spectrum of potential bone turnover biomarkers compared to other studies. Moreover, this study included the assessment of the correlation between these molecules with the FRAX scores of the 10-year risk of a major osteoporotic fractures and 10-year probability of a hip fracture. We identified that both sRANKL levels and sRANKL/OPG ratio can be used as biomarkers of osteoporosis, and an association with the estimated 10-years risk to the major osteoporotic and hip fracture assessed by FRAX in patients with RA was found. However, other molecules, such as DKK-1 and SOST, require further investigation to support our results in RA patients.

Nevertheless, several limitations of our study should be considered. Our study included RA patients with a long disease duration, and the characteristics of marker levels could be affected by disease duration. Therefore, further studies should include nontreated patients with early RA. In addition, considering the cross-sectional design of this study, further longitudinal studies should be performed to identify if these patients with higher serum levels of sRANKL or SOST have a major incidence of fractures compared to patients with normal levels. Although FRAX is a useful tool for predicting the risk of major osteoporotic fractures or hip fracture in RA, many patients can develop osteoporotic fractures even with low FRAX scores. Therefore, the utility of these biomarkers, namely sRANKL levels and sRANKL/OPG ratio, can be considered potential clinical tools that help predict future fractures in RA patients.

5. Conclusions

This study identifies that high sRANKL levels and the sRANKL/OPG ratio can be useful to detect a subgroup of patients with RA who had an increase in the 10-year risk of a major osteoporotic fracture and the 10-year risk of a hip fracture. High levels of sRANKL and an elevated sRANKL/OPG ratio were associated with osteoporosis. In contrast, SOST correlated negatively with the risk fractures assessed by FRAX. The determination of the sRANKL and sRANKL/OPG ratio can complement the findings of the FRAX score by predicting a clinical subgroup of patients with a high risk of developing osteoporotic fractures. We propose that the measurement of these molecules can contribute to identify RA patients at high risk of osteoporotic fractures by allowing clinicians to focus on the decision-making process when treating this high-risk group of patients.

Data Availability

The datasets generated during this study are available from corresponding authors on responsible request.

Ethical Approval

We performed this study following the lineament of the Helsinki declaration (Fortaleza, Brazil, 2013) [46]. This project was approved by the Institutional Research and Ethics Board of the Hospital (number of approval R-2015-1301-100).

Consent

All the included participants were informed about the aims of the study, and previous to their inclusion signed a voluntary consent. All authors declare their consent for publication.

Conflicts of Interest

All authors declare that they have no conflict of interest to disclosure.

Authors’ Contributions

CA Nava-Valdivia contributed to the methodology, investigation, writing, original draft, review and editing, formal analysis, and final approval. JM Ponce-Guarneros contributed to the methodology, investigation, writing, original draft, review and editing, formal analysis, and final approval. AM Saldaña-Cruz contributed to the investigation, original draft, review and editing, and final approval. EG Corona-Sánchez contributed to the investigation, original draft, review and editing, and final approval. M Ramírez-Villafañá contributed to the investigation, original draft, review and editing, formal analysis, and final approval. EE Perez-Guerrero contributed to the investigation, original draft, review and editing, formal analysis, and final approval. JD Centeno-Valadez contributed to the investigation, original draft, review and editing, formal analysis, and final approval. B Contreras-Haro contributed to the investigation, original draft, review and editing, and final approval. JD Murillo-Saich contributed to the investigation, original draft, review and editing, formal analysis, and final approval. B Contreras-Haro contributed to the investigation, original draft, review and editing, and final approval. ML Vazquez-Villegas contributed to the investigation, original draft, review and editing, and final approval. D Bonilla-Lara contributed to the investigation, original draft, review and editing, and final approval. M Ramirez-Villafaña contributed to the investigation, original draft, review and editing, formal analysis, and final approval. H Jacobo-Cuevas contributed to the investigation, original draft, and final approval. MF Alcaraz-Lopez contributed to the investigation, original draft, and final approval. EG Cardona-Muñoz contributed to the investigation, original draft, and final approval. S Cerpa-Cruz contributed to the investigation, original draft, and final approval. MF Alcaraz-Lopez contributed to the investigation, original draft, and final approval. EG Cardona-Muñoz contributed to the investigation, original draft, and final approval. EG Cardona-Muñoz contributed to the investigation, original draft, and final approval. M Salazar-Paramo contributed to the investigation, original draft, review and editing, supervision, and final approval. L Gonzalez-Lopez contributed to the conceptualization, methodology, investigation, resources, supervision,
project administration, original draft, writing, review and editing, and final approval. JJ Gamez-Nava contributed to the conceptualization, methodology, investigation, resources, funding acquisition, supervision, project administration, original draft, writing, review and editing, and final approval. CA Valdivia and JM Ponce-Guarneros contributed equally to this work and should be considered both as first authors.

Acknowledgments

Dr. Laura Gonzalez-Lopez and Dr. Jorge I. Gamez-Nava have current appointments: Programa de Doctorado en Farmacología, Departamento de Fisiología and Programa de Doctorado en Salud Pública, Departamento de Salud Pública, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara. Dr. Laura Gonzalez-Lopez and Dr. Jorge I. Gamez-Nava have currently the status of jubilate of the Instituto Mexicano del Seguro Social (IMSS). This project was financed by a grant from the Instituto Mexicano del Seguro Social (IMSS) and the Fondo de Investigación en Salud (FIS) (Grant number FIS/IMSS/PROT/G15/1455).

Supplementary Materials

Supplementary Table 1 shows the comparison between groups of patients divided by the severity of the FRAX score for major osteoporotic fractures. Higher sRANKL levels were observed in the group with a 10-year risk of major osteoporotic fractures > 20%, compared with the group with a 10-year risk of major osteoporotic fractures between 10 and 20% and the group with a 10-year risk of major osteoporotic fractures < 10% (p < 0.001). Similarly, the higher sRANKL/OPG ratio was observed in the group with a 10-year risk of major osteoporotic fractures > 20%, compared to other two groups (p = 0.001). Instead, the lower serum concentrations of SOST were observed in the group with a 10-year risk of major osteoporotic fractures > 20%, compared with the other groups (p < 0.001). No statistical differences were observed in the other biomarker levels between these three groups. Supplementary Table 2 shows the comparison between groups of RA patients divided by the severity of the FRAX score for hip fracture. Higher sRANKL levels were observed in the group with a 10-year risk of hip fracture > 10%, compared with the group of a 10-year risk of hip fracture between 3 and 10% and the group of a 10-year risk of hip fracture < 3% (p < 0.001). Similarly, the higher sRANKL/OPG ratio was observed in the group with a 10-year risk of hip fracture > 10%, compared to other two groups (p < 0.001). Instead, lower serum concentrations of SOST were observed in the group with a 10-year risk of hip fracture > 10%, compared with the other groups (p = 0.016). We did not observe significant statistical differences in the other biomarker levels between these three groups. (Supplementary Materials)

References

[1] J. A. Singh, K. G. Saag, S. L. Bridges et al., “2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis,” Arthritis & Rheumatology, vol. 68, no. 1, pp. 1–26, 2016.
[2] E. H. S. Choy and G. S. Panayi, “Cytokine pathways and joint inflammation in rheumatoid arthritis,” The New England Journal of Medicine, vol. 344, no. 12, pp. 907–916, 2001.
[3] P. Oelzner, A. Schwabe, G. Lehmann et al., “Significance of risk factors for osteoporosis is dependent on gender and meno-pause in rheumatoid arthritis,” Rheumatology International, vol. 28, no. 11, pp. 1143–1150, 2008.
[4] Y. Wang, R. Zhao, Z. Gu, C. Dong, G. Guo, and L. Li, “Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis,” Osteoporosis International, vol. 31, no. 8, pp. 1401–1409, 2020.
[5] L. Gonzalez-Lopez, J. I. Gamez-Nava, A. Vega-Lopez et al., “Performance of risk indices for identifying low bone mineral density and osteoporosis in Mexican mestizo women with rheumatoid arthritis,” The Journal of Rheumatology, vol. 39, no. 2, pp. 247–253, 2012.
[6] J. T. Schousboe, J. A. Shepherd, J. P. Bilezikian, and S. Baim, “Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry,” Journal of Clinical Densitometry, vol. 16, no. 4, pp. 455–466, 2013.
[7] J. A. Kanis, A. Oden, H. Johansson, F. Borgström, O. Ström, and E. McCloskey, “FRAX® and its applications to clinical practice,” Bone, vol. 44, no. 5, pp. 734–743, 2009.
[8] P. Fardellone, E. Salawati, L. Le Monnier, and V. Goeb, “Bone loss, osteoporosis, and fractures in patients with rheumatoid arthritis: a review,” Journal of Clinical Medicine, vol. 9, no. 10, p. 3361, 2020.
[9] R. Phuan-udom, N. Lektrakul, and W. Katchaman, “The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 37, no. 10, pp. 2603–2610, 2018.
[10] T. T. Cheng, S. F. Yu, F. M. Su et al., “Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture,” Arthritis Research & Therapy, vol. 20, no. 1, p. 16, 2018.
[11] J. A. Kanis and J. A. Kanis, “Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report,” Osteoporosis International, vol. 4, no. 6, pp. 368–381, 1994.
[12] P. D. Delmas, R. Eastell, P. Garnero, M. J. Seibel, and J. Stepan, “The use of biochemical Markers of bone turnover in osteoporosis,” Osteoporosis International, vol. 11, Supplement 6, pp. S2–S17, 2000.
[13] S. Xu, Y. Wang, J. Lu, and J. Xu, “Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis,” Rheumatology International, vol. 32, no. 11, pp. 3397–3403, 2012.
[14] P. Oelzner, S. Franke, G. Lehmann et al., “Soluble receptor activator of NF-kappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover,” Clinical Rheumatology, vol. 26, no. 12, pp. 2127–2135, 2007.
[15] M. Rossini, O. Viapiana, S. Adami et al., “In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density,” Clinical and Experimental Rheumatology, vol. 33, no. 1, pp. 77–83, 2015.
[16] J. Paccou, R. Mentaverri, C. Renard et al., “The relationships between serum sclerostin, bone mineral density, and vascular calcification in rheumatoid arthritis,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 12, pp. 4740–4748, 2014.

[17] F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis & Rheumatism, vol. 31, no. 3, pp. 315–324, 1988.

[18] M. L. L. Prevoo, M. A. van'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 38, no. 1, pp. 44–48, 1995.

[19] M. H. Cardiel, M. Abel-Bo, R. Ruíz-Mercado, and D. Alarcon-Segovia, “How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI),” Clinical and Experimental Rheumatology, vol. 11, no. 2, pp. 117–121, 1993.

[20] R Core Team, R: a language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria, 2020, https://www.R-project.org/2020.

[21] J. H. Lee, Y. K. Sung, C. B. Choi et al., “The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis,” BMC Musculoskeletal Disorders, vol. 17, no. 1, p. 98, 2016.

[22] A. E. Kearsn, S. Khosla, and P. K. Costen, “Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease,” Endocrine Reviews, vol. 29, no. 2, pp. 155–192, 2008.

[23] T. Wada, T. Nakashima, N. Hiroshi, and J. M. Penninger, “RANKL/RANK signaling in osteoclastogenesis and bone disease,” Trends in Molecular Medicine, vol. 12, no. 1, pp. 17–25, 2006.

[24] J. E. Aubin and E. Bonnelle, “Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption,” Medscape Women’s Health, vol. 5, no. 2, p. 5, 2000.

[25] A. Rogers and R. Eastell, “Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment,” The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 11, pp. 6323–6331, 2005.

[26] I. Nabipour, B. Larijani, K. Vahdat et al., “Relationships among serum receptor of nuclear factor-κB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women,” Menopause, vol. 16, no. 5, pp. 950–955, 2009.

[27] J. M. Liu, H. Y. Zhao, G. Ning et al., “Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75,” Calcified Tissue International, vol. 76, no. 1, pp. 1–6, 2005.

[28] N. S. Mykhailovska, I. O. Sletiskiuk, T. O. Kulychny, S. V. Gorbachova, and I. V. Zhulkevych, “The interrelationship of bone and cardiovascular remodeling biomarkers and clinical peculiarities of coronary artery disease in postmenopausal women,” Reumatologija, vol. 58, no. 3, pp. 142–149, 2020.

[29] V. Krishnan, H. U. Bryant, and O. A. Macdougald, “Regulation of bone mass by Wnt signaling,” The Journal of Clinical Investigation, vol. 116, no. 5, pp. 1202–1209, 2006.

[30] E. Pitters, E. Boudin, and W. Van Hul, “Wnt signaling: a win for bone,” Archives of Biochemistry and Biophysics, vol. 473, no. 2, pp. 112–116, 2008.

[31] B. T. Macdonald, K. Tamai, and X. He, “Wnt/β-catenin signaling: components, mechanisms, and diseases,” Developmental Cell, vol. 17, no. 1, pp. 9–26, 2009.

[32] J. J. Pinzone, B. M. Hall, N. K. Thudi et al., “The role of Dickkopf-1 in bone development, homeostasis, and disease,” Blood, vol. 113, no. 3, pp. 517–525, 2014.

[33] R. Wagner, G. Zhu, B. Q. Zhang et al., “The therapeutic potential of the Wnt signaling pathway in bone disorders,” Current Molecular Pharmacology, vol. 4, no. 1, pp. 14–25, 2011.

[34] R. L. Van Bezojoen, P. Dijkse, S. E. Papapoulos, and C. W. G. Lőwik, “SOST/sclerostin, an osteocyte-derived negative regulator of bone formation,” Cytokine & Growth Factor Reviews, vol. 16, no. 3, pp. 319–327, 2005.

[35] W. Balemans, E. Pitters, E. Cleiren et al., “The binding between sclerostin and LRPS is altered by DKK1 and by high-bone mass LRPS mutations,” Calcified Tissue International, vol. 82, no. 6, pp. 445–453, 2008.

[36] X. Li, Y. Zhang, H. Kang et al., “Sclerostin binds to LRPS/6 and antagonizes canonical Wnt signaling,” The Journal of Biological Chemistry, vol. 280, no. 20, pp. 19883–19887, 2005.

[37] P. Garnero, E. Sornay-Rendu, F. Munoz, O. Borel, and R. D. Chappurat, “Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study,” Osteoporosis International, vol. 24, no. 2, pp. 489–494, 2013.

[38] C. Wehmeyer, S. Frank, D. Beckmann et al., “Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction,” Science Translational Medicine, vol. 8, no. 330, article 330ra35, 2016.

[39] W. Balemans, M. Ebeling, N. Patel et al., “Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST),” Human Molecular Genetics, vol. 10, no. 5, pp. 537–543, 2001.

[40] G. Courbon, R. Lamarque, M. Gerbaix et al., “Early sclerostin expression explains bone formation inhibition before arthritis onset in the rat adjuvant-induced arthritis model,” Scientific Reports, vol. 8, no. 1, p. 3492, 2018.

[41] T. Ueland, L. Stilgren, and J. Bollerslev, “Bone matrix levels of Dickkopf and sclerostin are positively correlated with bone mass and strength in postmenopausal osteoporosis,” International Journal of Molecular Sciences, vol. 20, no. 12, p. 2896, 2019.

[42] M. M. Ardawi, A. A. Rouzi, S. A. al-Sibiani, N. S. al-Senani, M. H. Qari, and S. A. Moussa, “High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research study,” Journal of Bone and Mineral Research, vol. 27, no. 12, pp. 2592–2602, 2012.

[43] J. Coulson, L. Bagley, L. Barnouin et al., “Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults,” Osteoporosis International, vol. 28, no. 9, pp. 2683–2689, 2017.

[44] A. Arasu, P. M. Cawthon, L. Y. Lui et al., “Serum sclerostin and risk of hip fracture in older Caucasian women,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, pp. 2027–2032, 2012.
[45] S. Reppe, A. Noer, R. M. Grimholt et al., “Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women,” *Journal of Bone and Mineral Research*, vol. 30, no. 2, pp. 249–256, 2015.

[46] World Medical Association, “World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects,” *JAMA*, vol. 310, no. 20, pp. 2191–2194, 2013.